Pia Dosenovic team

Studies B cells for the development of new vaccines.

Research focus

B cell responses are a critical component for the protection against infections provided by vaccines. The activation of B cells is however highly regulated, to make sure the body does not mount immune responses to self-antigens, or develop un-controllable cell division, which could lead to cancer.

To generate vaccines that elicit protective and long-lasting immune responses against pathogens such as HIV-1, influenza and other emerging viruses, we use genetically modified mouse models with B cells expressing human antibodies that enable us to define the trajectory and quality of antigen-specific B cells after immunization.

We are also testing novel approaches for vaccine design such as using anti-idiotypic antibodies to stimulate a pathogen-specific B cell response.

Collectively, our research aims to study B cell responses on the molecular and cellular levels to provide information on B cell regulation that can help develop new vaccines against HIV-1 as well as other genetically variable- and emerging pathogens.

 

Members

Pia Dosenovic

Assistant professor
C1 Department of Microbiology, Tumor and Cell Biology

Rafael Marques

Research assistant

Manon Termote

PhD student

Isabel Baken

Master student
C1 Department of Microbiology, Tumor and Cell Biology

Selected publications

Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses.
Dosenovic P, Pettersson AK, Wall A, Thientosapol ES, Feng J, Weidle C, et al
J. Exp. Med. 2019 Oct;216(10):2316-2330

Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity.
Dosenovic P, Kara EE, Pettersson AK, McGuire AT, Gray M, Hartweger H, et al
Proc. Natl. Acad. Sci. U.S.A. 2018 05;115(18):4743-4748

Progress toward active or passive HIV-1 vaccination.
Escolano A, Dosenovic P, Nussenzweig MC
J. Exp. Med. 2017 01;214(1):3-16

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.
Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, et al
Immunity 2016 09;45(3):483-496

Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.
Escolano A, Steichen JM, Dosenovic P, Kulp DW, Golijanin J, Sok D, et al
Cell 2016 Sep;166(6):1445-1458.e12

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.
McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, et al
Nat Commun 2016 Feb;7():10618

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.
Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, et al
Cell 2015 Jun;161(7):1505-15

Antibodies in HIV-1 vaccine development and therapy.
Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC
Science 2013 Sep;341(6151):1199-204

BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses.
Dosenovic P, Soldemo M, Scholz JL, O'Dell S, Grasset EK, Pelletier N, et al
J. Immunol. 2012 Jun;188(12):6018-26

Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization.
Dosenovic P, Chakrabarti B, Soldemo M, Douagi I, Forsell MN, Li Y, et al
J. Immunol. 2009 Sep;183(5):3373-82

Funding

Current funding:

  • Karolinska Institutet
  • The Swedish Research Council (VR)
  • The European Research Council (ERC starting grant 2019)
  • Knut och Alice Wallenberg Foundation (Wallenberg Academy Fellow)

 

Previous funding:

  • K99 Pathway to Independence Award (NIH)
  • The Swedish Research Council (VR)
  • Karolinska Institutet